4.10.1.2Vertical
Allergy Management Organizations
PE-backed platforms consolidating allergy and immunology practices.
Market snapshot
These figures describe Allergy & Immunology (4.10.1), the segment that Allergy Management Organizations sits within — not Allergy Management Organizations on its own.
FragmentationConsolidatingEstimate
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so allergy and immunology is not separately sized.
Business model & economics
Revenue model
Testing, immunotherapy, and biologic-infusion reimbursement
Key economics
- Recurring revenue
- High
- EBITDA margin
- 18–28%
- Capex intensity
- Low
recurring immunotherapy visits
Characteristics
- Recurring in-office immunotherapy revenue.
- Rising allergy/asthma prevalence and biologics.
- Early MSO and PE roll-up interest.
M&A deal context
Deal activityModerate
Who’s acquiring
- Emerging allergy MSO platforms
- PE-backed consolidators
- Multispecialty acquirers
What’s driving deals
- Emerging allergy roll-up.
- Allergy/asthma and biologics demand.
- Recurring immunotherapy economics.
Find Allergy Management Organizations acquisition targets
Search Acquisera’s index for companies classified under Allergy Management Organizations (4.10.1.2) and build a targeted deal pipeline.
Search companies